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Introduction 
The number of patients with chronic kidney disease (CKD) continues to increase worldwide. 
Approximately 80% of patients with CKD and nearly 100% of patients with end-stage renal 
disease develop hypertension as a complication, and the presence of hypertension causes 
further progression of CKD, resulting in a vicious cycle. One of relevant principal 
mechanisms that cause hypertension in CKD is systemically or locally increased activity of 
the renin–angiotensin system, mainly mediated by the angiotensin II (Ang II) type 1 receptor 
(AT1R). The AT1R-associated protein (ATRAP) is a low molecular weight protein that 
specifically binds to AT1R. Previous studies have shown that ATRAP promotes constitutive 
internalization of AT1R and functions as an endogenous inhibitor that suppresses AT1R 
hyperactivation at local tissue sites (Daviet L et al., 1999; Tamura K et al., 2013).  
The remnant kidney model, which is created using 5/6 nephrectomy to reduce renal mass 
in rodents, mimics many features of human CKD and is widely used as a progressive CKD 
model. In the present study, we hypothesized that dysregulation of renal ATRAP expression 
and subsequent AT1R hyperactivation contributes to development of hypertension that 
occurs as a complication of the remnant kidney CKD model. To examine this hypothesis, we 
compared changes in endogenous ATRAP expression between 129/Sv and C57BL/6 mice 
using the remnant kidney model after 5/6 nephrectomy. We also examined the effect of 
ATRAP deficiency in C57BL/6 mice (with a hypertension-resistant strain background) on 
blood pressure regulation after 5/6 nephrectomy. 
 
Methods 
We used the remnant kidney model to compare renal function and blood pressure during 
CKD in two mouse strains (10-11 weeks old C57BL/6 and 129/Sv mice). Four weeks after 
surgery, renal function (assessed using estimated creatinine clearance) and systolic blood 
pressure by tail-cuff method were measured. In addition, we compared renal ATRAP mRNA 
expression. To investigate that a reduction in renal ATRAP expression is involved in 
pathogenesis of remnant kidney CKD model, we examined the effect of ATRAP deficiency on 
blood pressure in response to using ATRAP-knockout (KO) mice on C57BL/6 background. In 
addition, we compared plasma volume, renal function and renal expression of the major 
sodium transporters. 
 
Results 
Four weeks after surgery, renal function was similarly decreased in both mouse strains after 
remnant kidney model procedures (5/6 nephrectomy), compared with sham-operated mice. 
While systolic blood pressure remained stable in C57BL/6 mice after 5/6 nephrectomy, it 
increased in 129/Sv mice 4 weeks after 5/6 nephrectomy compared with sham-operated mice. 
Renal ATRAP mRNA expression in the C57BL/6 mouse remnant kidney CKD model 
significantly increased compared with sham-operated mice. Whereas, renal ATRAP mRNA 
expression decreased in the 129/Sv mouse remnant kidney CKD model compared with sham-
operated mice. At 4 weeks after 5/6 nephrectomy, systolic blood pressure significantly 
elevated in ATRAP-KO remnant kidney model (KO-RK) mice  compared with WT remnant 
kidney model (WT-RK) mice (KO-RK vs WT-RK mice, 124.2±2.4 vs 106.6±0.9mmHg, 
P<0.001). Although 5/6 nephrectomy did not affect plasma volume in WT mice (WT-RK mice), 
it significantly increased plasma volume in ATRAP-KO mice (KO-RK mice) (Figure). Moreover, 
in ATRAP-KO mice compared with wild-type C57BL/6 mice after 5/6 nephrectomy, renal 
expression of the epithelial sodium channel α-subunit (αENaC) and tumor necrosis factor-α 
(TNF-α) were significantly enhanced. 
 
Discussion 
Our results here indicate that failure of the ATRAP compensatory mechanism, which is an 
endogenous inhibitor of AT1R hyperactivation, plays an important role in causing 
hypertension in a mouse CKD model. Although we found that 5/6 nephrectomy causes an 
increase in blood pressure in 129/Sv mice, in C57BL/6 mice blood pressure was similar to 
that of sham-operated mice (Ma LJ., et al 2003; Leelahavanichkul A., et al 2010). To explore 
the molecular mechanisms involved in hypertension pathogenesis in our remnant kidney 
CKD model, we exploited this strain difference in hypertension susceptibility between 129/Sv 
and C57BL/6 mice in response to 5/6 nephrectomy. Furthermore, we focused our analysis 
on the functional role of the ATRAP-mediated compensatory mechanism, as a proposed 
endogenous inhibitor of AT1R hyperactivation, in regulation of blood pressure in the remnant 
kidney CKD model. 
5/6 nephrectomy-induced changes in renal ATRAP expression were in opposition in 129/Sv 
and C57BL/6 mice. In C57BL/6 mice, ATRAP showed antagonistic increases, which 
contributed to suppression of blood pressure elevation. Hypertension in the remnant kidney 
CKD model caused by genetic ATRAP deficiency in C57BL/6 mice supports this result. 
Although ATRAP-KO mice that underwent 5/6 nephrectomy exhibited a similar reduction in 
GFR as WT mice, their circulating plasma volume significantly increased. This suggests that 
increased circulating plasma volume and subsequent hypertension observed in the remnant 
kidney CKD model in ATRAP-KO mice is not correlated with decreased GFR. We also 
considered the possibility that renal sodium reabsorption is affected by ATRAP deficiency in 
the remnant kidney CKD model. Accordingly, we found that renal αENaC expression is 
significantly upregulated in ATRAP-KO mice compared with WT mice after 5/6 nephrectomy. 
Collectively, promotion of primary sodium reabsorption in the renal tubules of the remnant 
kidney via activation of the AT1R-TNF-α-αENaC axis is a plausible mechanism for the 
increased circulating plasma volume observed in ATRAP-KO mice after 5/6 nephrectomy 
(Sriramula S and Francis J, 2015; DiPetrillo K., et al 2014; Czikora I., et al 2014).  
In conclusion, our results indicate that reduction of renal ATRAP plays a key role in onset 
and progression of hypertension that is a complication of CKD. Indeed, ATRAP may be a 
therapeutic target for hypertension treatment in CKD, and ATRAP activation therapy may be 
able to control hypertension associated with CKD. 
 
 
 
 
 
 
 
 
 
 
Weeks after surgery 
a
b
Sham RK Sham RK
** 
** 
†† 
†† 
** 
4 weeks after surgery 
P
la
s
m
a
 v
o
lu
m
e
(μ
l/
g
B
W
)
WT
KO
WT-Sham
WT-RK
KO-Sham
KO-RK
0 2 4 8
S
y
s
to
li
c
 b
lo
o
d
 p
re
s
s
u
re
 
(m
m
H
g
)
100
110
120
130
40
50
60
70
 
 
Figure. Effect of ATRAP deficiency on blood pressure and plasma volume after 5/6 
nephrectomy in C57BL/6 mice on a hypertension-resistant strain background  
(a) Effect of sham operation or 5/6 nephrectomy on blood pressure in WT and ATRAP-KO 
mice. Systolic blood pressure was measured before and at 2, 4, and 8 weeks after sham 
procedure or 5/6 nephrectomy. Values are expressed as mean ± SE (n = 8 in each group). **P 
< 0.01 vs sham, ††P < 0.01 vs WT mice, two-way repeated measures ANOVA. (b) Effect of 5/6 
nephrectomy on plasma volume in WT and ATRAP-KO mice. Plasma volume was measured 
using the Evans Blue dilution method at 4 weeks after sham procedure or 5/6 nephrectomy. 
Values are expressed as mean ± SE (n = 8–9 in each group). **P < 0.01 vs sham, ††P < 0.01 
vs WT mice, two-way ANOVA. WT, wild-type mice; KO, ATRAP-KO mice; Sham, sham 
procedure control; RK, remnant kidney model 
 
References 
Czikora I, Alli A, Bao HF, Kaftan D, Sridhar S, Apell HJ, Gorshkow B, White R, Zimmermann 
A, Wendel A, Pauly-Evers M, Hamacher J, Garcia-Gabay I, Fischer B, Verin A, Baqi Z, Pittet 
JF, Shabbir W, Lemmens-Gruber R, Chakraborty T, Lazarak A, Matthay MA, Eaton DC, Lucas 
R. (2014), A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium 
channel activation. Am J Respir Crit Care Med. 190, 522-32. 
 
Daviet L, Lehtonen JY, Tamura K, Griese DP, Horiuchi M, Dzau VJ. (1999), Cloning and 
characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 
receptor. J Biol Chem. 274, 17058-62. 
 
DiPetrillo K, Coutermarsh B, Soucy N, Hwa J, Gesek F. (2014), Tumor necrosis factor induces 
sodium retention in diabetic rats through sequential effects on distal tubule cells. Kidney Int, 
65, 1676-83. 
 
Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, 
Harrison DG. (2007), Role of T cell in the genesis of angiotensin II-induced hypertension and 
vascular dysfunction. J Exp Med. 204(10), 2449-60.  
 
Leelahavanichkul A, Yan Q, Hu X, Eisner C, Huang Y, Chen R, Mizel D, Zhou H, Wright EC, 
Kopp JB, Schnermann J, Yuen PS, Star RA. (2010), Angiotensin II overcomes strain-
dependent resistance of rapid CKD progression in a new remnant kidney mouse model. 
Kidney Int. 78, 1136-53.  
 
Lopez-Ilasaca M, Liu X, Tamura K, Dzau VJ. (2003), The angiotensin II type I receptor-
associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II 
signaling. Mol Biol Cell. 14, 5038-5050. 
 
Ma LJ, Fogo AB. (2003), Model of robust induction of glomerulosclerosis in mice: importance 
of genetic background. Kidney Int. 64, 350-5. 
 
Sriramula S, Francis J. (2015), Tumor Necrosis Factor - Alpha Is Essential for Angiotensin II-
Induced Ventricular Remodeling: Role for Oxidative Stress. PLoS One 10, e0138372. 
 
Tamura K, Wakui H, Maeda A, Dejima T, Ohsawa M, Azushima K, Kanaoka T, Haku S, Uneda 
K, Masuda S, Azuma K, Shigenaga A, Koide Y, Tsurumi-Ikeya Y, Matsuda M, Toya Y, Tokita Y, 
Yamashita A, Umemura S. (2013), The physiology and pathophysiology of a novel angiotensin 
receptor-binding protein ATRAP/Agtrap. Curr Pharm Des. 19, 3043-8. 
 
Tanabe K, Lanaspa MA, Kitagawa W, Rivard CJ, Miyazaki M, Klawitter J, Schreiner GF, 
Saleem MA, Mathieson PW, Makino H, Johnson RJ, Nakagawa T. (2012), Nicorandil as a 
novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse. Am J Physiol 
Renal Physiol. 302, F1151-60. 
 
Wakui H, Tamura K, Masuda S, Tsurumi-Ikeya Y, Fujita M, Maeda A, Ohsawa M, Azushima K, 
Uneda K, Matsuda M, Kitamura K, Uchida S, Toya Y, Kobori H, Nagahama K, Yamashita A, 
Umemura S. (2013), Enhanced angiotensin receptorassociated protein in renal tubule 
suppresses angiotensin-dependent hypertension. Hypertension. 61, 1203–1210. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
論文目録 
 
I  主論文 
An angiotensin II type 1 receptor binding molecule has a critical role in hypertension in a 
chronic kidney disease model 
 
Ryu Kobayashi, Hiromichi Wakui, Kengo Azushima, Kazushi Uneda, Sona Haku, Kohji 
Ohki, Kotaro Haruhara, Sho Kinguchi, Miyuki Matsuda, Masato Ohsawa, Yoshiyuki Toya, 
Akira Nishiyama, Akio Yamashita, Katsuyuki Tanabe, Yohei Maeshima, Satoshi Umemura,  
Kouichi Tamura: Kidney international: Kidney International. In press.  
 
II 副論文 
Effect of Single-pill Irbesartan/Amlodipine Combination Therapy on Clinic and Home 
Blood Pressure Profiles in Chronic Kidney Disease Patients with Hypertension  
 
Ryu Kobayashi, Kouichi Tamura, Hiromichi Wakui, Kengo Azushima, Masato Ohsawa, 
Sona Haku, Kazushi Uneda, Kohji Ohki, Kotaro Haruhara, Sho Kinguchi, Satoshi 
Umemura: Clin Exp Hypertens. In press. 
 
III  参考論文 
1. Comparison of Direct Renin inhibitor and Angiotensin II Receptor Blocker on Clinic and 
Ambulatory Blood Pressure Profiles in Hypertension with Chronic Kidney Disease.  
 
Uneda K, Tamura K, Wakui H, Azushima K, Haku S, Kobayashi R, Ohki K, Haruhara K, 
Kinguchi S, Ohsawa M, Fujikawa T, Umemura S: Clin Exp Hypertens. In press. 
 
2. Effects of pitavastatin add-on chronic kidney disease with albuminuria and dyslipidemia 
 
Ohsawa M, Tamura K, Wakui H, Kanaoka T, Azushima K, Uneda K, Haku S, Kobayashi 
R, Ohki K, Haruhara K, Kinguchi S, Toya Y, Umemura S: Lipids Health Dis. 14(161), 
Epub 2015 Dec. 
3. Effects of the oriental herbal medicine Bofu-tsusho-san in obesity hypertension: a 
multicenter, randomized, parallel-group controlled trial (ATH-D-14-01021.R2).  
 
Azushima K, Tamura K, Haku S, Wakui H, Kanaoka T, Ohsawa M, Uneda K, Kobayashi 
R, Ohki K, Dejima T, Maeda A, Hashimoto T, Oshikawa J, Kobayashi Y, Nomura K, 
Azushima C, Takeshita Y, Fujino R, Uchida K, Shibuya K, Ando D, Tokita Y, Fujikawa T, 
Umemura S: Atherosclerosis. 240(1) 297-304, 2015 May 
 
4. Renal Tubule Angiotensin II Type 1 Receptor–Associated Protein Promotes Natriuresis 
and Inhibits Salt-Sensitive Blood Pressure Elevation. 
 
Wakui H, Uneda K, Tamura K, Ohsawa M, Azushima K, Kobayashi R, Ohki K, Dejima T, 
Kanaoka T, Tsurumi‐Ikeya Y, Matsuda M, Haruhara K, Nishiyama A, Yabana M, Fujikawa 
T, Yamashita A, Umemura S: J Am Heart Assoc. 4(3): e001594, 2015 March. 
 
5. Effects of the Angiotensin receptor blocker olmesartan on adipocyte hypertrophy and 
function in mice with metabolic disorders. 
 
Maeda A, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, Kanaoka T, Kobayashi 
R, Ohki K, Matsuda M, Tsurumi-Ikeya Y, Yamashita A, Tokita Y, Umemura S: Biomed 
Res Int. 2014:946492, Epub 2014 Jun 2. 
 
6. Effects of Ang II Receptor Blocker Irbesartan on Adipose Tissue Function in Mice with 
Metabolic Disorders. 
 
Maeda A, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, Kobayashi R, Tsurumi-
Ikeya Y, Kanaoka T, Dejima T, Ohki K, Haku S, Yamashita A, Umemura S: Int J Med Sci. 
11(6):646-51, 2014 Apr 27. 
 
 
 
7. Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-
visit blood pressure variability and parameters of renal and vascular function in 
hypertensive patients with chronic kidney disease. 
 
Azushima K, Uneda K, Tamura K, Wakui H, Ohsawa M, Kobayashi R, Dejima T, Kanaoka 
T, Maeda A, Toya Y, Umemura S: Biomed Res Int. Volume 2014: Article ID 437087, Epub 
2014 Apr 
 
8. Deletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium 
reabsorption and exacerbates angiotensin II-mediated hypertension. 
 
Ohsawa M, Tamura K, Wakui H, Maeda A, Dejima T, Kanaoka T, Azushima K, Uneda K, 
Tsurumi-ikeya Y, Kobayashi R, Matsuda M, Uchida S, Toya Y, Kobori H, Nishiyama A, 
Yamashita A, Ishikawa Y, Umemura S: Kidney Int. 86(3) 570-81, 2014 Apr 
 
9. Bofu-tsu-shosan, an oriental herbal medicine, exerts a combinational favorable 
metabolic modulation including antihypertensive effect on a mouse model of human 
metabolic disorders with visceral obesity. 
 
Azushima K, Tamura K, Wakui H, Maeda A, Ohsawa M, Uneda K, Kobayashi R, Kanaoka 
T, Dejima T, Fujikawa T, Yamashita A, Toya Y, Umemura S: PLos One. 8(10): e75560, 
2013 Oct. 
 
10. L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition 
improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in 
hypertension with chronic kidney disease. 
 
Kanaoka T, Tamura K, Wakui H, Ohsawa M, Azushima K, Uneda K, Kobayashi R, 
Fujikawa T, Tsurumi-Ikeya Y, Maeda A, Yanagi M, Toya Y, Umemura S: Int J Mol Sci. 
14(8):16866-81, 2013 Aug 16. 
 
11. Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure 
profile and cardiorenal function better than addition of benazepril in chronic kidney 
disease. 
 
Ohsawa M, Tamura K, Kanaoka T, Wakui H, Maeda A, Dejima T, Azushima K, Uneda K, 
Kobayashi R, Tsurumi-Ikeya Y, Toya Y, Fujikawa T, Umemura S: Int J Mol Sci. 14(8): 
15361-75, 2013 Jul 24. 
 
12. Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect 
on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension. 
 
Wakui H, Dejima T, Tamura K, Uneda K, Azuma K, Maeda A, Ohsawa M, Kanaoka T, 
Azushima K, Kobayashi R, Matsuda M, Yamashita A, Umemura S: Cardiovasc Res. 
100(3):511-9, 2013 Dec 1. 
